The city of Sarasota, Florida, currently has 19 active clinical trials seeking participants for Lung Cancer research studies.
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT06150664
Recruiting
This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: Florida Cancer Specialists - Sarasota, Sarasota, Florida
Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma
Register for Updates
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06040541
Recruiting
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Register for Updates
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04180371
Recruiting
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: * Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab * Learn more about the side effects of BT5528 * Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
Register for Updates
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies
NCT04152499
Recruiting
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types: 1. Triple negative breast cancer 2. Epithelial ovarian cancer 3. Non-small cell lung cancer 4. Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma 5. Smal... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Florida Cancer Specialists and Research Institute, Sarasota, Florida
Conditions: Gastric Adenocarcinoma, Breast Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Epithelial Ovarian Cancer, Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma
Register for Updates
Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening
NCT04968548
Recruiting
This study is part of the development and validation of a non-invasive lung screening test which aim to identify early stage lung cancer in patients at high risk for lung cancer.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
03/28/2024
Locations: Sarasota Memorial Hospital, Sarasota, Florida
Conditions: Lung Cancer
Register for Updates
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
NCT04354246
Recruiting
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/10/2024
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC
Register for Updates
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
NCT05708950
Recruiting
The goal of this clinical trial is to test the safety and efficacy of KVA12123 alone or combined with pembrolizumab in patients with advanced solid tumors. The main questions this study aims to answer are: What is the safety of KVA12123 when administered alone and in combination with pembrolizumab to advanced cancer patients? What is an appropriate dose of KVA12123 to administer alone and in combination with pembrolizumab to advanced cancer patients in future clinical trials? Participants in t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/11/2023
Locations: Sarah Cannon Research Institute at Florida Cancer Specialists, Sarasota, Florida
Conditions: Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer
Register for Updates